Is CJC-1295 safe?
For the version most people are asking about, the pairing with ipamorelin, there is no answer: no published study has given the two to people together, so no safety trial exists for the combination.1 CJC-1295 on its own has been through two short trials in healthy adults, which reported no serious adverse reactions,2 and it has an FDA entry that names two adverse events and calls the clinical data limited.3
- Longest of them
- Forty-nine days.2
- What they reported
- No serious adverse reactions, and a conclusion calling it safe and relatively well tolerated at the doses studied.2
- What the FDA lists
- Increased heart rate and a systemic vasodilatory reaction, under a heading for substances whose nomination was withdrawn.3
- Trials of the pairing
- None published.1
- Approval
- Neither form is approved by a major regulator.1
Where CJC-1295 is sold
ElitePhysiqMD
$315.00 per month
- What it is
- dose not stated
- What it buys
- Ipamorelin, with CJC-1295, with or without DAC not stated
- Read
- September 2026
Longevixx
$329 per month
- What it is
- dose not stated
- What it buys
- Ipamorelin, with CJC-1295, with or without DAC not stated
- Read
- September 2026
What the two trials in people reported
The main one was a pair of dose-escalation studies: “The study design was two randomized, placebo-controlled, double-blind, ascending dose trials with durations of 28 and 49 d.”2 The people in them were volunteers, not patients — “Healthy subjects, ages 21-61 yr, were studied.”2 The safety line in that paper is one sentence long:
No serious adverse reactions were reported.
The conclusion goes a little further, describing what happened “in healthy adults and was safe and relatively well tolerated”, and it attaches that judgment to the particular doses tested rather than to the molecule in general.2 The second study was smaller and built for a different question: “GH pulsatility was assessed by 20-min blood sampling during an overnight 12-h period in healthy 20- to 40-yr-old men”4 It found that the hormone kept its natural rhythm under a long stimulus — “GH secretion was increased after CJC-1295 administration with preserved pulsatility.”4
What the FDA has published, and on which list
The FDA’s compounding page carries two separate tables, and CJC-1295 is in the second one, the list it describes this way: “This list of bulk drug substances previously in category 2 of the interim policies were withdrawn by the nominators.”3 So its entry records a nomination that was pulled, not a substance the agency currently evaluates. Ipamorelin acetate is in the other table, category 2, which ipamorelin side effects covers.
FDA has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction.
The entry does not say where those events were seen, in how many people, or on what dose, and the sentence that follows is the agency’s own qualifier: “Available clinical data are limited.”3 It adds a manufacturing concern as well, that compounded drugs containing it “Compounded drugs containing CJC-1295 may pose risk for immunogenicity for certain routes of administration”.3 The page was read in September 2026.
That leaves two documents pointing in different directions: a 2006 trial that saw nothing serious in seven weeks, and a regulator that lists two adverse events without a denominator. Both are printed here because both are the record, and neither is strong enough to overturn the other.
Which CJC-1295 the question is about
Two different molecules are sold under this name, and only one of them has ever been in a human trial. The long-acting version carries a drug affinity complex, the modification that “The DAC modification enables binding to circulating albumin, markedly prolonging exposure and enabling a more sustained pharmacodynamic effect after a single administration.”1 That is the one the 2006 studies used, and the one this site records a half-life for.
The version most sellers actually list is the other one. A 2026 review of the class says of it that it “remains essentially uncharacterised in the peer-reviewed human literature”, and that “To date, no controlled clinical studies have directly evaluated this compound in humans”.1 Its own table gives the clearance figure for that form as “t½ not reported in human studies”.1
Which one a given vial holds is not always obvious from a listing. Which CJC-1295 are you buying sets out how sellers here name each form, and what CJC-1295 does covers the hormone response each version has or has not been measured to produce.
The pairing nobody has tested
Search PubMed for CJC-1295 alongside adverse events, safety, tolerability or death and twelve records come back. Two are the trials above, one is a study of what people post on forums, and nine are reviews published in 2026. None of them gave CJC-1295 and ipamorelin to people together. The ipamorelin search returns eleven records and the same result.
The 2026 review describes the pairing as a practice rather than a protocol, noting that ipamorelin “ipamorelin is also frequently discussed in combination with CJC-1295 (typically the non-DAC form)” and that “this practice is largely driven by anecdotal rationale, and controlled clinical evidence supporting synergy or meaningful body-composition outcomes in healthy individuals remains limited”.1
What each molecule has been timed at separately is on the results timeline, and how the two classes reach growth hormone by different routes is on GHRH analogs vs ghrelin mimetics.
Questions that come next
Is CJC-1295 with ipamorelin safe?
Nobody has measured it. No published study has given the two to people together,1 so there is no safety finding about the combination in either direction. The individual records are above.
What side effects have been reported?
Is CJC-1295 FDA approved?
No. The review this site cites states that neither variant is approved by a major regulator.1 Where all five molecules stand is on which of these is FDA approved.
Does it raise cancer risk?
Nothing read for this site reports a cancer finding for CJC-1295, in either direction, and neither 2006 trial ran long enough to look. The one molecule here whose label addresses cancer is tesamorelin — is tesamorelin safe prints that warning in the label’s own shape.
How does it compare with sermorelin?
Both act on the GHRH receptor, and they are separated mainly by how long they last. CJC-1295 vs sermorelin compares them field by field.
Sources
4 documents, in the order the figures above use them. The date on each is the one printed on the document.
- Dominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Document date: 2026-06-18. PMID 42395176, PMC13322892, doi:10.3389/fendo.2026.1822475. Read September 2026.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.Document date: 2006-03. PMID 16352683, doi:10.1210/jc.2005-1536. Read September 2026.
- Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.Document date: content current as of 04/22/2026. Category 2 of the bulk substances nominated under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act. Read September 2026.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.Document date: 2006-12. PMID 17018654, doi:10.1210/jc.2006-1702. Read September 2026.